• Detects SNVs, Indels, rearrangement, and copy number gain
• Assesses biomarkers TMB and MSI
• Identifies gene deletion and mono- vs. bi-allelic loss of function
• CLIA-certified assay for blood and tissue
• Adopted by leading biopharmas in global clinical trials
Whole blood
Plasma
FFPE
4-10 mL blood*
2-5 mL plasma
≥1mm³ tissue (5-10 FFPE slides)
Plasma: 6 Days
Tissue: 10 Days
*CLIA-certified assay requires two tubes of 10mL whole blood
PredicineATLAS™ assay is designed to help biopharmaceutical partners identify patients with the right molecular profile for their clinical program, assess response to investigational drugs or combination therapies, and detect presence of residual disease, recurrence, or relapse.
In clinical studies, PredicineATLAS™ showed high performance in longitudinal assessment of cfDNA across multiple solid tumors to identify patients responding to therapeutics. The data here demonstrates a deep reduction in variant allele frequency (VAF) among responders to immune checkpoint inhibitor therapy in biliary tract cancer.1
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.
If you have any questions or need assistance, complete this form and we will respond within 24 hours.
1Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). Do-Youn Oh et al. Journal of Clinical Oncology 2020 38:15_suppl, 4520-4520
